Researchers have discovered a biological pathway through which the hormone GDF15 protects against liver inflammation independently of weight loss. Published on August 10, 2026, the findings reveal that the hormone activates a brain-to-liver signaling route, suppressing scarring and immune damage in metabolic dysfunction-associated steatohepatitis.
Scientists investigating the hormone GDF15 have uncovered a mechanism that operates quite differently from its well-known role in curbing appetite. Researchers at McMaster University found that the hormone protects against advanced fatty liver disease through a distinct neurological connection rather than through caloric restriction or weight loss alone, as the McMaster outlet reported.
How the Brain-to-Liver Signaling Pathway Works
The research, published on August 10, 2026, in Cell Metabolism, demonstrates that GDF15 prompts communication from the brain to the nervous system. This signaling triggers the release of glucocorticoids, which are steroid hormones critical for managing stress responses, metabolism, and immune functions. According to the McMaster publication, these glucocorticoids actively dampen liver inflammation without requiring any changes in food intake, overall body weight, or liver fat levels.
“Our findings show that GDF15 does much more than regulate appetite and body weight,” says Gregory Steinberg, professor in McMaster University’s Department of Medicine, co-director of the Centre for Metabolism, Obesity and Diabetes Research (MODR), and senior author of the study. “We discovered that GDF15 activates a natural brain-to-liver signaling pathway that helps suppress liver inflammation and reduce fibrosis. This changes how we think about the hormone and suggests it may be part of the body’s own defense system against chronic liver injury.”
Gregory Steinberg, professor in McMaster University’s Department of Medicine, co-director of the Centre for Metabolism, Obesity and Diabetes Research (MODR), and senior author of the study, via McMaster
Building upon earlier work from 2023 that linked GDF15 to calorie burning during weight loss, the team utilized advanced spatial technology alongside genetic, pharmacological, and genomic models mimicking human metabolic dysfunction-associated steatohepatitis, or MASH. The results indicate that the hormone limits the progression of liver fibrosis, which is the accumulation of scar tissue characteristic of advanced disease.
“GDF15 helps reprogram liver cells to reduce inflammation and scarring by advanced spatial technology,” says Dongdong Wang, first and corresponding author of the study and assistant professor McMaster’s Department of Medicine. “Instead of causing liver damage, GDF15 appears to help calm the liver’s immune system. It shifts immune cells into a more protective and less active state, helping reduce inflammation and prevent damage to the liver.”
Dongdong Wang, first and corresponding author of the study and assistant professor McMaster’s Department of Medicine, via McMaster
Implications for MASH and Future Combination Therapies
Millions of people worldwide suffer from MASH, a severe progression of fatty liver disease that can eventually result in cirrhosis, liver failure, or liver cancer. While recent weight-loss drugs have helped many patients, liver inflammation frequently persists even after significant weight reduction. The McMaster report notes that current medical therapies primarily target body weight and liver fat.
Researchers suggest that future medical strategies could combine weight-loss medications with therapies designed to directly target inflammation by harnessing the body’s natural defense mechanisms.
“Current therapies largely focus on reducing body weight and liver fat,” says Steinberg. “Our work suggests there may be value in combining those approaches with therapies that directly target inflammation. By understanding how the body naturally protects the liver, we can identify new opportunities to develop more effective treatments for people living with MASH.”
Gregory Steinberg, professor in McMaster University’s Department of Medicine, co-director of the Centre for Metabolism, Obesity and Diabetes Research (MODR), and senior author of the study, via McMaster
Kuhre and Sebastian B. Novo Nordisk also supplied research support and the GDF15 hormone used in the investigation.
Читайте также
